Prognostic value of disseminated tumor cells (DTC) identification in bone marrow from patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma (interim results)

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Ekaterina Obarevich

Citation

Annals of Oncology (2015) 26 (suppl_9): 8-15. 10.1093/annonc/mdv518

Authors

E.S. Obarevich¹, N.S. Besova², N.N. Tupitsyn³, M.M. Davydov⁴, V.A. Gorbunova², T.A. Titova²

Author affiliations

¹ Chemotherapy, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
² Chemotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow/RU
³ Haematopoiesis Immunology Lab., N. N. Blokhin Russian Cancer Research Center, Moscow/RU
⁴ Thoraco-abdominal, N. N. Blokhin Russian Cancer Research Center, Moscow/RU

Abstract 1146

Aim/Background

To identify DTC in bone marrow (BM) as a therapeutically significant target to predict survival of patients with stage IV gastric cancer.

Methods

A total of 27 patients with advanced gastric cancer were enrolled, median age 52 years. All patients received thriplet chemotherapy. Baseline BM-DCT were identified by flow cytometry. BM-DTC positivity was defined as at least 1 tumor cell per 10 million myelokaryocytes.

Results

BM-DTC were found in 18 of 27 patients. Median survival was 6.5 months in BM-DTC positive vs. 9.2 months in BM-DTC negative patients (p = 0.019). The table below summarizes the clinicomorphological findings. Table. Relationship between DTC-positivity and clinicomorphological parameters.

Parameter	BM-DTC positive patients n, %	BM-DTC negative patients n, %	p-Value
Tumor site
Esophagogastric junction	9/18 (50)	1/9 (11.1)	0.049
Body of stomach	6/18 (33.3)	4/9 (44.4)	0.573
Anthrum	3/18 (16.7)	2/9 (22.2)	0.726
Total stomach	0/18 (0)	2/9 (22.2)	0.038
Adenocarcinoma histology
Moderately differentiated	4/18 (22.2)	2/9 (22.2)	1
Poorly differentiated	10/18 (55.6)	1/9 (11.1)	0.027
Signet-ring cell	4/18 (22.2)	6/9 (66.7)	0.024
Metastasis sites
Liver	6/18 (33.3)	3/9 (33.3)	1
Peripheral lymph nodes	4/18 (22.2)	3/9 (33.3)	0.535
Retroperitoneal lymph nodes	8/18 (44.4)	2/9 (22.2)	0.260
Ovaries	1/18 (5.6)	1/9 (11.1)	0.603
Peritoneal carcinomatosis	9/18 (50)	8/9 (88.9)	0.049

Conclusions

The presence of DTC in BM of patients with advanced gastric cancer is a poor prognostic factor associated with a high risk of early progression. BM-DTC were identified significantly more frequently in cases with EGJ and total gastric cancer, and in patients free from peritoneal carcinomatosis; there was also a correlation with tumor histology. The study is in ongoing

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

19 Dec 2015